Former President and Chief Executive Officer of Vascular Pathways
Life Science Partner has recruited Bill Bold, former CEO of Vascular Pathways and senior medical device leader, to become Chief Executive Officer for Vestagen, an innovator in the development of Active Barrier fabrics and protection technology to protect the healthcare worker.
Prior to joining Vestagen, Bold turned around Vascular Pathways with product innovation and commercialization and sold the company to CR Bard for its best-in-class portfolio of peripheral vascular access technologies. “Bold is an articulate, strategic and a strong leader who recruits world-class teams to early-stage companies,” stated Tom Callaway, MD, Founder and President of Life Science Partner and Venture Partner at HealthQuest Capital, an investor in the company.
“With a track record for delivering a strong return on investment in fundraising with venture capital and private equity, Bold has the experience to lead Vestagen’s growth and profitability within the healthcare industry,” noted Callaway.
Prior to joining Vascular Pathways, Bold held executive leadership roles for both early stage and corporate divisions of medical device companies such as Access Scientific, Venetec, Medibuy and CR Bard.
Bold earned a Bachelor of Science Degree in Marketing from West Chester University.